Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Exact Sciences Earns 2025 Great Place To Work® Certification™
10:00am, Monday, 12'th May 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® f
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
12:52pm, Friday, 02'nd May 2025
Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue de
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
09:18am, Friday, 02'nd May 2025
Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
08:30am, Friday, 02'nd May 2025
Exact Sciences ends the first quarter of 2025 on a solid note.
Exact Sciences to Participate in May Investor Conference
06:00am, Friday, 02'nd May 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript
08:47pm, Thursday, 01'st May 2025
Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Ch
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Thursday, 01'st May 2025
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.50 per share a year ago.
Exact Sciences Announces First-Quarter 2025 Results
04:05pm, Thursday, 01'st May 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Wednesday, 30'th Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:09am, Thursday, 24'th Apr 2025
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 23'rd Apr 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
06:00am, Tuesday, 22'nd Apr 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to d
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
04:00pm, Monday, 14'th Apr 2025
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
06:00am, Monday, 14'th Apr 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Onco
Exact Sciences Schedules First Quarter 2025 Earnings Call
06:00am, Tuesday, 01'st Apr 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 20
